MA45805A1 - Anti-met antibodies, bispecific antigen-binding molecules binding to met, and methods of use thereof - Google Patents
Anti-met antibodies, bispecific antigen-binding molecules binding to met, and methods of use thereofInfo
- Publication number
- MA45805A1 MA45805A1 MA45805A MA45805A MA45805A1 MA 45805 A1 MA45805 A1 MA 45805A1 MA 45805 A MA45805 A MA 45805A MA 45805 A MA45805 A MA 45805A MA 45805 A1 MA45805 A1 MA 45805A1
- Authority
- MA
- Morocco
- Prior art keywords
- binding
- met
- antigen
- binding molecules
- bispecific antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 11
- 102000036639 antigens Human genes 0.000 title abstract 11
- 108091007433 antigens Proteins 0.000 title abstract 11
- 238000000034 method Methods 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940125644 antibody drug Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des anticorps et des molécules bispécifiques de liaison à l'antigène qui se lient à met et des procédés d'utilisation de ceux-ci. Les molécules bispécifiques de liaison à l'antigène comprennent un premier et un second domaine de liaison à l'antigène, les premier et second domaines de liaison à l'antigène se liant à deux épitopes différents (de préférence non chevauchants) du domaine extracellulaire du met humain. Les molécules bispécifiques de liaison à l'antigène sont capables de bloquer l'interaction entre met humain et son ligand hgf. Les molécules bispécifiques de liaison à l'antigène peuvent présenter une activité agoniste minimale ou nulle de met, par exemple , par comparaison avec des molécules de liaison à l'antigène monovalent qui comprennent uniquement l'un des domaines de liaison à l'antigène de la molécule bispécifique, qui tend à exercer une activité agoniste de met non souhaitée. L'invention concerne également des conjugués anticorps-médicament (adc) comprenant les anticorps ou les molécules bispécifiques de liaison à l'antigène fournies par la présente invention liés à un agent cytotoxique, un radionucléide, ou une autre fraction, ainsi que des méthodes de traitement du cancer chez un sujet par l'administration au sujet d'une molécule bispécifique de liaison à l'antigène ou d'un adc de celle-ci.The invention relates to antibodies and bispecific antigen-binding molecules that bind to met and methods of using them. The bispecific antigen-binding molecules include a first and a second antigen-binding domain, the first and second antigen-binding domains binding to two different (preferably non-overlapping) epitopes of the extracellular domain of the human put. Bispecific antigen-binding molecules are able to block the interaction between human met and its hgf ligand. Bispecific antigen-binding molecules may show minimal or no agonist activity of met, for example, compared to monovalent antigen-binding molecules which include only one of the antigen-binding domains of the bispecific molecule, which tends to exert unwanted met agonist activity. Also provided are antibody-drug (adc) conjugates comprising the antibodies or bispecific antigen-binding molecules provided by the present invention linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an adc thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423068P | 2016-11-16 | 2016-11-16 | |
| PCT/US2017/061757 WO2018093866A1 (en) | 2016-11-16 | 2017-11-15 | Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45805A1 true MA45805A1 (en) | 2019-12-31 |
| MA45805B2 MA45805B2 (en) | 2021-11-30 |
Family
ID=65895504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45805A MA45805B2 (en) | 2016-11-16 | 2017-11-15 | Anti-met antibodies, bispecific antigen-binding molecules binding to met, and methods of use thereof |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR110165A1 (en) |
| MA (1) | MA45805B2 (en) |
-
2017
- 2017-11-15 MA MA45805A patent/MA45805B2/en unknown
- 2017-11-15 AR ARP170103179A patent/AR110165A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR110165A1 (en) | 2019-03-06 |
| MA45805B2 (en) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501014A1 (en) | Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof | |
| MA44312A (en) | ANTIBODIES AND THEIR METHODS OF USE | |
| MA43458A1 (en) | Novel peptides, peptide combinations and carriers for use in the immunotherapeutic treatment of various cancers | |
| MA38194B1 (en) | Anti-ceacam5 antibodies and their uses | |
| MA47313A (en) | SUBCUTANEOUS FORMULATIONS OF HER2 ANTIBODIES | |
| EA200800355A1 (en) | NEUTRALIZING HUMAN ANTIBODIES AGAINST B7RP1 | |
| MA38496B2 (en) | Biologically active molecules, their conjugates, and therapeutic uses | |
| MA43490A1 (en) | New peptides and combination of peptides for use in immunotherapy against various cancers | |
| EA202091587A1 (en) | ANTI-TIGIT ANTIBODIES AND THEIR APPLICATION AS THERAPEUTIC AND DIAGNOSTIC AGENTS | |
| MA44693A1 (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
| MA43435B1 (en) | NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 25 - MRAX5-003) | |
| MA41521A1 (en) | Novel cell epitopes and new combination of cell epitopes for use in immunotherapy of myeloma and other cancers | |
| EA201100694A1 (en) | ANTIBODY TO CD38 PERSON AND ITS APPLICATION | |
| MA41932B1 (en) | Methods of treating or preventing migraines | |
| MA32568B1 (en) | Pharmaceutical preparations containing dopamine receptor bonds | |
| MA30876B1 (en) | ANTIBODIES OF LYMPHOTOXIN-ALPHA | |
| MX2021010003A (en) | HIGH AFFINITY ANTI-MERTK ANTIBODIES AND THEIR USES. | |
| MA39378A1 (en) | Igf-1r antibody and its use as an addressing vehicle for the treatment of cancer | |
| MA37761A1 (en) | Proteins for binding to a double receptor antagonist antigen and their uses | |
| MX2021010114A (en) | Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met. | |
| EA202090116A1 (en) | COMPOSITIONS CONTAINING CONJUGATES OF CANNABINOID ANALOGUE AND METHODS OF APPLICATION | |
| FR3063645B1 (en) | ACEFAPC FOR THE TREATMENT OF ACETYLCHOLINE DEPENDENT DISEASES | |
| WO2019032945A9 (en) | Cd40-binding agents and uses thereof | |
| Maaland et al. | Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003 | |
| EA202190755A1 (en) | AGENTS FOR CANCER THERAPY AND DIAGNOSIS |